Ivo Abraham, PhD, highlights follow-on biologics as a pathway to a more equitable global health care system by reducing costs ...

Biotech company Amgen (NASDAQ:AMGN) reported Q1 CY2025 results topping the market’s revenue expectations, with sales up 9.4% ...

High rates of biologic naivety, limited switching, and ongoing unmet needs across the gMG landscape create opportunity for brand differentiation.EXTON, PA, May 15, 2025 (GLOBE NEWSWIRE) -- The ...

Discover why Dr. Reddy’s Laboratories remains a strong buy amid robust revenue growth, underappreciated pipeline potential, ...

We believe that Merck KGaA enjoys a narrow moat, driven by intangible assets and switching costs which are prevalent in its Life Science and Electronics businesses. A few acquisitions to fill gaps in ...

With fiscal 2025 being a low base year due to losses, earnings per share are forecast to more than double by financial year ...

Discover "Bevacizumab - Biosimilar Insight, 2025," which analyzes 25+ companies and 30+ drugs in the bevacizumab biosimilars landscape. The report covers marketed drugs, pipeline molecules, and ...

AbbVie just delivered a financial flex with a $13.3 billion quarter, blowing past expectations—its adjusted earnings per ...

Discover Coherus BioSciences' strategic shift to oncology with Q1 2025 insights on LOQTORZI growth, pipeline progress, and revenue projections up to $200M.

Sirius Therapeutics Inc. raised nearly $50 million in a series B2 financing round May 9 to support its pipeline of small interfering RNA (siRNA) molecules for cardiovascular disease indications.

Selardsdi is indicated for the treatment of moderate to severe plaque psoriasis and active psoriatic arthritis in adults and ...

We recently compiled a list of the 11 Stocks That Will Bounce Back According To Analysts. In this article, we are going to ...